| Literature DB >> 27748869 |
Jian Wan1, Yi Shan1, Yibo Fan2, Conghui Fan2, Song Chen2, Jie Sun2, Lili Zhu2, Long Qin2, Mengjin Yu2, Zhaofen Lin1.
Abstract
Toll-like receptor (TLR) family are receptors for extracellular or intracellular signaling, such as lipopolysaccharide (LPS), or 12-O-tetradecanoylphorbol-13-acetate. TLR induces the differentiation of human myeloid monocytic‑leukemia cells (THP-1) to macrophages. However, the relationship between extracellular or intracellular signaling and the TLR protein level remain to be determined. Using RT-PCR and western blot analysis, the aim of the present study was to determine whether TLR4, a major TLR family member, could be moderately upregulated by high concentration of LPS and whether it promoted the maturation of THP1 cells. The results showed that, upregulated TLR4 at the protein level and mRNA level enriched the TLR4 modulation style. In addition, TLR4 expression was blocked by nuclear factor (NF)-κB inhibitor, and LPS stimulated NF-κB binding in the TLR4 gene promoter. Therefore, the increased expression of TLR4 in the responsiveness of LPS-treated THP1 cells occurred in response to the upregulation of their respective receptors, as well as a tight binding of NF-κB in the TLR4 gene promoter.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27748869 PMCID: PMC5101966 DOI: 10.3892/mmr.2016.5825
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
Figure 2.LPS-induced activation of TLR4 is required to upregulate TLR4 expression. (A) LPS-induced TLR4 activation. (B) Inhibition of TLR4 activation prevents TLR4 feedback loop. (C) FACS showed TLR4 protein expression after treatment with TLR4 inhibitor in the absence or presence of LPS stimulation in the cell membrane. LPS stimulation condition was 4 h and at 20 ng/m LPS. TLR4 signaling inhibitor was CLI-095, 50 nmol/l. LPS, lipopolysaccharide; TLR4, Toll-like receptor 4.
Figure 1.LPS upregulated TLR4 expression, especially at a high concentration of LPS. (A) Morphology of THP1 cells under LPS stimulation. (B) RT-PCR tested TLR4 expression in the three treatment groups of THP1 cells, respectively. (C) TLR4 protein expression in the cell membrane using FACS. Three groups' treatment include: i) Mock group with PBS; ii) low LPS group with time of 15 min exposure and concentration of LPS at 1 ng/ml; and iii) high LPS group with time of 4 h exposure and concentration of LPS at 20 ng/ml. LPS, lipopolysaccharide; TLR4, Toll-like receptor 4.
Figure 3.NF-κB targeted TLR4 in chromatin and promotes TLR4 expression. (A) ChIP assay for NF-κB binding to TLR4 gene promoter. (B) Blocking NF-κB activation blocked TLR4 expression. (C) TLR4 protein expression in the cell membrane by FACS. Three group treatment: i) Mock group, LPS stimulation without any inhibitor; ii) STAT3 inhibitor group, LPS stimulation with STAT3 inhibitor; and iii) NF-κB inhibitor group, LPS stimulation with NF-κB inhibitor. LPS stimulation condition was 4 h and at 20 ng/ml LPS. STAT3 inhibitor was STA-21 (sc-200757; Santa Cruz Biotechnology, Inc.), 2 µmmol/l. NF-κB inhibitor was helenalin (sc-218579; Santa Cruz Biotechnology, Inc.), 5 µmmol/l. NF-κB, nuclear factor-κB; TLR4, Toll-like receptor 4; ChIP, chromatin immunoprecipitation; LPS, lipopolysaccharide.